Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Trigr.

    Client Virtual Booth

    TRIGR

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Trigr
    europepng-1561025764png-1574931246png-1574932008png-1622461635png-1622462181 Flag
    Country
    Country
    Europe
    Address
    Address
    --
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.trigr.org/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.

    Details:

    Compass Therapeutics obtains global rights to TR009, a novel bispecific antibody and inhibitor of the notch pathway targeting DLL4 and VEGF-A.


    Lead Product(s): CTX-009

    Therapeutic Area: Oncology Product Name: TR009

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Compass Therapeutics

    Deal Size: $14.0 million Upfront Cash: Undisclosed

    Deal Type: Acquisition May 13, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009

    Details:

    Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territory.


    Lead Product(s): Asciminib

    Therapeutic Area: Oncology Product Name: ABL001

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Elpiscience

    Deal Size: $117.0 million Upfront Cash: $7.0 million

    Deal Type: Collaboration January 20, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search